Cargando…

Fidaxomicin as a Salvage Therapy for Fulminant Clostridioides difficile Infection

Few studies have demonstrated the efficacy of fidaxomicin in the treatment of fulminant Clostridioides difficile infection (CDI). Fidaxomicin has been used as part of the standard treatment for nonsevere and severe CDI according to the guidelines by the Infectious Diseases Society of America and the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heleno, Caio T, Tagintsev, Aleksey, Lasley, Katharine, Summerfield, Douglas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2021
Materias:	Internal Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8301726/ https://www.ncbi.nlm.nih.gov/pubmed/34327111 http://dx.doi.org/10.7759/cureus.16559

Ejemplares similares

Fulminant Clostridioides difficile Colitis With SARS-CoV-2 Infection
por: Duhan, Sanchit, et al.
Publicado: (2023)

Fidaxomicin Use for Clostridium Difficile Infection Probably Decreases the Effect of Coumadin® in Elderly
por: Dhruv, Samyak, et al.
Publicado: (2020)

Fidaxomicin Use in the Pediatric Population with Clostridioides difficile
por: Oliver, Meredith B, et al.
Publicado: (2022)

Fidaxomicin vs Vancomycin for the Treatment of a First Episode of Clostridium Difficile Infection: A Meta-analysis and Systematic Review
por: Al Momani, Laith A, et al.
Publicado: (2018)

Dormant Crohn's Disease Reactivated by Clostridioides difficile Infection
por: Hernandez, Oscar L, et al.
Publicado: (2023)

A prospective, observational study of fidaxomicin use for Clostridioides difficile infection in France
por: Guery, Benoit, et al.
Publicado: (2021)

Comparison of fidaxomicin to oral vancomycin for the treatment of Clostridioides difficile infection in hospitalized patients
por: Rao, A. Krishna, et al.
Publicado: (2022)

679. Retrospective Analysis of Vancomycin and Fidaxomicin for the Treatment of Recurrent Clostridioides difficile Infection
por: Fabian, Amy, et al.
Publicado: (2023)

Fidaxomicin to prevent recurrent Clostridioides difficile: what will it cost in the USA and Canada?
por: Patel, Devangi, et al.
Publicado: (2023)

692. The Role of Fidaxomicin for the Treatment of Clostridioides Difficile Infection in the Pediatric Population in the United States
por: Lee, Yuman, et al.
Publicado: (2023)

Diarrhea or No Diarrhea, It Still Hurts: An Atypical Case of Clostridioides difficile
por: Singla, Abhinav, et al.
Publicado: (2020)

An Unusual Presentation of Clostridioides Difficile Colitis in a Patient on Opioids
por: Ajibola, Oluwafemi A, et al.
Publicado: (2022)

722. Effectiveness of Fidaxomicin versus Oral Vancomycin in the Treatment of Recurrent Clostridioides difficile
por: Rinaldi, Alyssa, et al.
Publicado: (2020)

Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of Clostridioides (Clostridium) difficile Infection
por: Dubberke, Erik R, et al.
Publicado: (2020)

392. Guideline adaptation of fidaxomicin as first-line therapy for Clostridioides difficile infection in institutions across the United States
por: Basir, Angela, et al.
Publicado: (2022)

Appendectomy as a Potential Predisposing Factor for the Development of Recurrent and Fulminant Clostridium Difficile
por: Heindl, Stacey E, et al.
Publicado: (2020)

Emerging therapies for Clostridium difficile infection – focus on fidaxomicin
por: Chaparro-Rojas, Fredy, et al.
Publicado: (2013)

Correction to: Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United States
por: Jiang, Yiling, et al.
Publicado: (2022)

Fidaxomicin for the Treatment of Clostridioides difficile Infection in Adult Patients: An Update on Results from Randomized Controlled Trials
por: Giacobbe, Daniele Roberto, et al.
Publicado: (2022)

Real-World Budget Impact of Fidaxomicin versus Vancomycin or Metronidazole for In-Hospital Treatment of Clostridioides difficile Infection
por: Whitney, Laura, et al.
Publicado: (2023)

390. Eravacycline combination therapy for severe, recurrent, or fulminant Clostridioides difficile infection
por: Morrison, Austin R, et al.
Publicado: (2022)

Clostridioides difficile infection leading to fulminant colitis with toxic megacolon
por: Rajack, Fareed, et al.
Publicado: (2023)

Examining the Rate of Clostridioides (Formerly Clostridium) Difficile Infection Pre- and Post-COVID-19 Pandemic: An Institutional Review
por: Yadlapati, Sujani, et al.
Publicado: (2021)

Role of Fecal Microbiota Transplantation in Reducing Clostridioides difficile Infection-Associated Morbidity and Mortality: A Systematic Review
por: Ramesh, Adarsh Srinivas, et al.
Publicado: (2022)

Clostridioides difficile Infection in Inflammatory Bowel Disease Patients: A Systematic Review of Risk Factors and Approach in Management
por: Sangurima, Leslie, et al.
Publicado: (2023)

Fidaxomicin - the new drug for Clostridium difficile infection
por: Vaishnavi, Chetana
Publicado: (2015)

Microbiological Characterization and Clinical Outcomes After Extended-Pulsed Fidaxomicin Treatment for Clostridioides difficile Infection in the EXTEND Study
por: Wilcox, Mark H, et al.
Publicado: (2019)

797. Management of Patients with Multiple Clostridioides difficile Infection Recurrences using a Tapered-Pulsed Fidaxomicin Strategy
por: Tan, Xing, et al.
Publicado: (2020)

A Systematic Review of the Efficacy and Safety of Fecal Microbiota Transplantation in the Treatment of Hepatic Encephalopathy and Clostridioides difficile Infection in Patients With Cirrhosis
por: Tun, Kyaw Min, et al.
Publicado: (2022)

674. Host and Pathogen Risk Factors for Fulminant Clostridioides difficile Infection
por: Chua, Hubert C, et al.
Publicado: (2023)

Gut microbiota and microbiota-based therapies for Clostridioides difficile infection
por: Chopra, Teena, et al.
Publicado: (2023)

Outcomes of Patients Who Developed Clostridioides difficile Infection During Hospitalization and Had a History of Comorbid Post-Traumatic Stress Disorder
por: Patel, Shivani J, et al.
Publicado: (2022)

Myxopyronin B inhibits growth of a Fidaxomicin-resistant Clostridioides difficile isolate and interferes with toxin synthesis
por: Brauer, Madita, et al.
Publicado: (2022)

The Risk of Clostridioides difficile Recurrence after Initial Treatment with Vancomycin or Fidaxomicin Utilizing Cerner Health Facts
por: Hall, Ronald G., et al.
Publicado: (2022)

682. Novel rpoB mutations and trends in clinical Clostridioides difficile isolates with reduced fidaxomicin susceptibility
por: Gonzales-Luna, Anne J, et al.
Publicado: (2023)

A Review on Clostridioides Difficile Testing and How to Approach Patients With Multiple Negative Tests: A Case Report
por: Bassi, Raghav, et al.
Publicado: (2023)

The long and sinuous road to phage-based therapy of Clostridioides difficile infections
por: Umansky, Andrew A., et al.
Publicado: (2023)

Laboratory markers predictive of fulminant Clostridioides difficile infection refractory to fluid resuscitation
por: Ahmad, Omar, et al.
Publicado: (2021)

Clinical Efficacy of Fidaxomicin and Oral Metronidazole for Treating Clostridioides difficile Infection and the Associated Recurrence Rate: A Retrospective Cohort Study
por: Mori, Nobuaki, et al.
Publicado: (2023)

668. The clinical effectiveness of Fidaxomicin compared to Vancomycin in the treatment of Clostridioides difficile infection in immunocompromised hosts, a single center study
por: Alsoubani, Majd, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vkfedh1vdjf3oe2eb8mp6ojrpu